AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMAN-LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY

Registry ID

BO39633

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2018-07-10

Completion date

2022-12-07

Last update

2017-04-25

Conditions

• UNSPECIFIED

Related clinical trials

• CONTINUING TREATMENT FOR SUBJECTS WHO HAVE PARTICIPATED IN A PRIOR PROTOCOL INVESTIGATING ELOTUZUMAB (CONTINUATION PHASE 2 ROLL-OVER PROTOCOL)
• AN OBSERVATIONAL, OPEN-LABEL, NON-RANDOMIZED STUDY TO MONTIOR FOR ADVERSE DRUG REACTIONS AMONG PATIENTS ADMINISTERED FEDORAK-MANUFACTURED [F-18]-FDG INJECTION
• INVESTIGATOR-INITIATED PHASE II STUDY OF PEMBROLIZUMAB IMMUNOLOGICAL RESPONSE EVALUATION (INSPIRE)
• EXPLORING THE EFFECTS OF PRAZOSIN ON BASAL DOPAMINE IN HEALTHY HUMANS: A [11C]-(+)-PHNO PET STUDY
• COMPARISON OF MAO-A VT BETWEEN HEALTHY MEN AND WOMEN MEASURED WITH [11C]-HARMINE PET

View on source registry